Polymeric Micelles for Multi-Drug Delivery in Cancer

被引：116

作者：

Cho, Hyunah ^{[1
,2
]}

Lai, Tsz Chung ^{[2
]}

Tomoda, Keishiro ^{[2
]}

Kwon, Glen S. ^{[2
,3
]}

机构：

[1] St Louis Coll Pharm, Dept Pharmaceut & Adm Sci, St Louis, MO 63110 USA

[2] Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, Madison, WI 53705 USA

[3] Korea Inst Sci & Technol KIST, Biomed Res Inst, Ctr Theragnosis, Seoul 136791, South Korea

来源：

AAPS PHARMSCITECH | 2015年 / 16卷 / 01期

基金：

新加坡国家研究基金会;

关键词：

controlled release; drug combination; drug delivery; drug solubilization; polymeric micelles; DRUG-DELIVERY; ACID) MICELLES; TUMOR-CELLS; PACLITAXEL; COMBINATIONS; DOXORUBICIN; EFFICACY; POLYSORBATE-80; NANOMEDICINE; CHEMOTHERAPY;

D O I：

10.1208/s12249-014-0251-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Drug combinations are common in cancer treatment and are rapidly evolving, moving beyond chemotherapy combinations to combinations of signal transduction inhibitors. For the delivery of drug combinations, i.e., multi-drug delivery, major considerations are synergy, dose regimen (concurrent versus sequential), pharmacokinetics, toxicity, and safety. In this contribution, we review recent research on polymeric micelles for multi-drug delivery in cancer. In concurrent drug delivery, polymeric micelles deliver multi-poorly water-soluble anticancer agents, satisfying strict requirements in solubility, stability, and safety. In sequential drug delivery, polymeric micelles participate in pretreatment strategies that "prime" solid tumors and enhance the penetration of secondarily administered anticancer agent or nanocarrier. The improved delivery of multiple poorly water-soluble anticancer agents by polymeric micelles via concurrent or sequential regimens offers novel and interesting strategies for drug combinations in cancer treatment.

引用

页码：10 / 20

页数：11

共 68 条

[1] Systems Pharmacological Analysis of Paclitaxel-Mediated Tumor Priming That Enhances Nanocarrier Deposition and Efficacy [J].

Ait-Oudhia, Sihem ;

Straubinger, Robert M. ;

Mager, Donald E. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 344 (01) :103-112

[2]

[Anonymous], 2012, Int. Scholarly Res. Not, DOI DOI 10.5402/2012/195727

[3] Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents [J].

Bae, Younsoo ;

Diezi, Thomas A. ;

Zhao, Anni ;

Kwon, Glen S. .

JOURNAL OF CONTROLLED RELEASE, 2007, 122 (03) :324-330

[4] Mixed pH-Sensitive Polymeric Micelles for Combination Drug Delivery [J].

Bae, Younsoo ;

Alani, Adam W. G. ;

Rockich, Nicole C. ;

Lai, T. S. Z. Chung ;

Kwon, Glen S. .

PHARMACEUTICAL RESEARCH, 2010, 27 (11) :2421-2432

[5] Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors [J].

Batist, Gerald ;

Gelmon, Karen A. ;

Chi, Kim N. ;

Miller, Wilson H., Jr. ;

Chia, Stephen K. L. ;

Mayer, Lawrence D. ;

Swenson, Christine E. ;

Janoff, Andrew S. ;

Louie, Arthur C. .

CLINICAL CANCER RESEARCH, 2009, 15 (02) :692-700

[6]

Batrakova EV, 2006, NANOPARTICULATES DRU, P63

[7] The causes and consequences of genetic heterogeneity in cancer evolution [J].

Burrell, Rebecca A. ;

McGranahan, Nicholas ;

Bartek, Jiri ;

Swanton, Charles .

NATURE, 2013, 501 (7467) :338-345

[8]

Cabral H, 2011, NAT NANOTECHNOL, V6, P815, DOI [10.1038/NNANO.2011.166, 10.1038/nnano.2011.166]

[9] Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy [J].

Canellos, George P. ;

Abramson, Jeremy S. ;

Fisher, David C. ;

LaCasce, Ann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1611-1615

[10] Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up [J].

Canellos, GP ;

Gollub, J ;

Neuberg, D ;

Mauch, P ;

Shulman, LN .

ANNALS OF ONCOLOGY, 2003, 14 (02) :268-272

← 1 2 3 4 5 6 7 →